TNF-Alpha Inhibition for Treatment of Alzheimer's Disease

Completed · Phase 1

Conditions studied: Alzheimer's Disease

In brief

It is widely believed that inflammation contributes to the pathogenesis of AD. TNF has been implicated in both AD and neurological inflammation. Anti-TNF therapy is therefore surmised to be of potential benefit for treating AD.

Key facts

Study ID

NCT00203320

Run by

Tobinick, Edward Lewis, M.D.

People needed

30

Starts

2005-04-01

Expected to finish

2006-01-01

Last updated by the study team

2006-04-24

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• NINCDS-ADRDA Criteria for Alzheimer's disease
• CT or MRI consistent with AD

You may not qualify if…

• active infection
• CHF
• demyelinating disease
• uncontrolled diabetes mellitus
• vascular dementia
• clinically significant neurologic disease other than AD
• Hachinski >4
• history of lymphoma
• TBC
• wbc<2500
• platelets<100,000
• HCT<30
• pregnancy
• premenopausal, fertile not on acceptable birth control
• change in neuroactive medication within 4 weeks of study initiation

Where it is running

• 100 UCLA Medical Plaza, Suites 205-210 — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.